JP2022526420A5 - - Google Patents
Info
- Publication number
- JP2022526420A5 JP2022526420A5 JP2021559535A JP2021559535A JP2022526420A5 JP 2022526420 A5 JP2022526420 A5 JP 2022526420A5 JP 2021559535 A JP2021559535 A JP 2021559535A JP 2021559535 A JP2021559535 A JP 2021559535A JP 2022526420 A5 JP2022526420 A5 JP 2022526420A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- chain variable
- variable region
- polypeptide sequence
- heavy chain
- Prior art date
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962830598P | 2019-04-08 | 2019-04-08 | |
| US62/830,598 | 2019-04-08 | ||
| US201962861377P | 2019-06-14 | 2019-06-14 | |
| US62/861,377 | 2019-06-14 | ||
| US201962896790P | 2019-09-06 | 2019-09-06 | |
| US62/896,790 | 2019-09-06 | ||
| US201962928615P | 2019-10-31 | 2019-10-31 | |
| US62/928,615 | 2019-10-31 | ||
| PCT/US2020/025643 WO2020210067A1 (en) | 2019-04-08 | 2020-03-30 | Humanized anti-dll3 chimeric antigen receptors and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022526420A JP2022526420A (ja) | 2022-05-24 |
| JPWO2020210067A5 JPWO2020210067A5 (https=) | 2022-06-15 |
| JP2022526420A5 true JP2022526420A5 (https=) | 2022-06-15 |
Family
ID=72750831
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021559535A Pending JP2022526420A (ja) | 2019-04-08 | 2020-03-30 | ヒト化抗ｄｌｌ３キメラ抗原受容体及びその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220184127A1 (https=) |
| EP (1) | EP3952888A1 (https=) |
| JP (1) | JP2022526420A (https=) |
| KR (1) | KR20210150432A (https=) |
| CN (1) | CN113795262A (https=) |
| AU (1) | AU2020271012A1 (https=) |
| BR (1) | BR112021016272A2 (https=) |
| CA (1) | CA3132202A1 (https=) |
| IL (1) | IL286984A (https=) |
| MX (1) | MX2021012336A (https=) |
| SG (1) | SG11202108759SA (https=) |
| WO (1) | WO2020210067A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018308088B2 (en) | 2017-07-25 | 2025-05-29 | Truebinding, Inc. | Treating cancer by blocking the interaction of TIM-3 and its ligand |
| AU2020214796A1 (en) | 2019-01-30 | 2021-07-29 | Truebinding, Inc. | Anti-Gal3 antibodies and uses thereof |
| JP7181438B2 (ja) * | 2019-08-06 | 2022-11-30 | アプリノイア セラピューティクス リミテッド | 病理学的タウ種に結合する抗体及びその使用 |
| WO2021242776A2 (en) | 2020-05-26 | 2021-12-02 | Truebinding, Inc. | Methods of treating inflammatory diseases by blocking galectin-3 |
| CN117529337A (zh) * | 2021-05-08 | 2024-02-06 | 上海齐鲁制药研究中心有限公司 | 针对dll3的结合分子及其应用 |
| JP2024532486A (ja) * | 2021-09-02 | 2024-09-05 | メモリアル スローン ケタリング キャンサー センター | Ｄｌｌ３を標的とする抗原認識受容体及びその使用 |
| CN114790240B (zh) * | 2022-06-10 | 2023-06-06 | 郑州大学 | SARS-CoV-2中和性单克隆抗体及应用 |
| CA3264572A1 (en) * | 2022-08-26 | 2024-02-29 | Juno Therapeutics, Inc. | DELTA-TYPE CHIMERICAL ANTIBODIES AND ANTIGENIC RECEPTORS (DLL3) |
| CN116813784B (zh) * | 2023-05-17 | 2024-03-01 | 星奕昂(上海)生物科技有限公司 | 靶向dll3的抗体及其应用 |
| CN120731224A (zh) * | 2024-01-30 | 2025-09-30 | 石药集团巨石生物制药有限公司 | 抗dll3抗体及应用 |
| WO2025212519A1 (en) * | 2024-04-01 | 2025-10-09 | Moonlight Bio, Inc. | Dll3 binding proteins and uses thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101522716B (zh) * | 2006-10-02 | 2013-03-20 | 瑞泽恩制药公司 | 抗人il-4受体的高亲和力人抗体 |
| JP2013507378A (ja) * | 2009-10-09 | 2013-03-04 | メルク・シャープ・エンド・ドーム・コーポレイション | 抗ｈｅｒ３抗体の製造、特徴づけ及びその用途 |
| EP3907242A1 (en) * | 2010-01-29 | 2021-11-10 | Chugai Seiyaku Kabushiki Kaisha | Anti-dll3 antibody |
| CN103003697A (zh) * | 2010-05-17 | 2013-03-27 | 得克萨斯系统大学董事会 | 来自动物的单克隆抗体的快速分离 |
| WO2012019061A2 (en) * | 2010-08-05 | 2012-02-09 | Stem Centrx, Inc. | Novel effectors and methods of use |
| WO2013020898A1 (en) * | 2011-08-05 | 2013-02-14 | Ifom Fondazione Istituto Firc Di Oncologia Molecolare | Constitutively active upar variants and their use for the generation and isolation of inhibitory antibodies |
| PE20190658A1 (es) * | 2012-02-24 | 2019-05-08 | Abbvie Stemcentrx Llc | Moduladores y metodos de empleo novedosos |
| CN103173413A (zh) * | 2012-12-07 | 2013-06-26 | 天津三箭生物技术有限公司 | 小鼠抗人β-Catenin单克隆抗体及分泌该单克隆抗体的杂交瘤细胞株 |
| GB201302447D0 (en) * | 2013-02-12 | 2013-03-27 | Oxford Biotherapeutics Ltd | Therapeutic and diagnostic target |
| US9879087B2 (en) * | 2014-11-12 | 2018-01-30 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
| MA41613A (fr) * | 2015-02-23 | 2018-01-02 | Abbvie Stemcentrx Llc | Récepteurs antigéniques chimériques anti-dll3 et procédés d'utilisation desdits récepteurs |
| TWI793062B (zh) * | 2015-07-31 | 2023-02-21 | 德商安美基研究（慕尼黑）公司 | Ｄｌｌ３及ｃｄ３抗體構築體 |
| MX2020004185A (es) * | 2017-09-27 | 2021-01-08 | Univ Southern California | Nuevas plataformas para coestimulacion, nuevos diseños car y otras mejoras para terapia celular adoptiva. |
| CA3097193A1 (en) * | 2018-05-08 | 2019-11-14 | Phanes Therapeutics, Inc. | Anti-dll3 antibodies and uses thereof |
-
2020
- 2020-03-30 CA CA3132202A patent/CA3132202A1/en active Pending
- 2020-03-30 CN CN202080027518.8A patent/CN113795262A/zh active Pending
- 2020-03-30 US US17/593,087 patent/US20220184127A1/en not_active Abandoned
- 2020-03-30 SG SG11202108759S patent/SG11202108759SA/en unknown
- 2020-03-30 BR BR112021016272A patent/BR112021016272A2/pt not_active Application Discontinuation
- 2020-03-30 EP EP20788157.4A patent/EP3952888A1/en not_active Withdrawn
- 2020-03-30 AU AU2020271012A patent/AU2020271012A1/en not_active Abandoned
- 2020-03-30 WO PCT/US2020/025643 patent/WO2020210067A1/en not_active Ceased
- 2020-03-30 KR KR1020217034403A patent/KR20210150432A/ko not_active Withdrawn
- 2020-03-30 JP JP2021559535A patent/JP2022526420A/ja active Pending
- 2020-03-30 MX MX2021012336A patent/MX2021012336A/es unknown
-
2021
- 2021-10-05 IL IL286984A patent/IL286984A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022526420A5 (https=) | ||
| JP2022526841A5 (https=) | ||
| JP2022527173A5 (https=) | ||
| US11155615B2 (en) | Anti-ROR1 antibodies | |
| US7939072B2 (en) | Anti-EGFR antibodies with an improved anti-tumor activity and compositions and articles of manufacture comprising same | |
| JP2020501531A5 (https=) | ||
| CN103533960B (zh) | c-KIT抗体及其用途 | |
| JP6359372B2 (ja) | ＤＡＲＰｉｎを含む二重特異キメラ蛋白質 | |
| JP2021514664A5 (https=) | ||
| IL276830B1 (en) | Anti-claudin 18.2 antibodies and their uses | |
| JP2020528750A5 (https=) | ||
| RU2014101669A (ru) | Агенты, связывающие белки r-спондины (rspo), и способы их применения | |
| JP2014531217A (ja) | ｃ−ＭｅｔのＳＥＭＡドメイン内のエピトープに特異的に結合する抗体 | |
| JP2021528047A5 (https=) | ||
| IL310938A (en) | Anti-CCR8 antibodies and their uses | |
| HRP20150256T1 (hr) | Djelatna sredstva za vezanje notch1-receptora i postupci njihove uporabe | |
| JPWO2019173420A5 (https=) | ||
| CN111278861A (zh) | Pd-l1抗体、其抗原结合片段及医药用途 | |
| US20250388682A1 (en) | Degradation of egfr using a bispecific binding agent | |
| US20250270323A1 (en) | Hhla2 binding agents with novel activity | |
| JPWO2020210067A5 (https=) | ||
| US9499622B2 (en) | Anti-EGFR/anti-HER2 bispecific antibodies with anti-EGFR DARPins | |
| JPWO2020205331A5 (https=) | ||
| JPWO2019217145A5 (https=) | ||
| JPWO2020210247A5 (https=) |